Evidence map›Paper›PMID 40276829›Full record

ReviewThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi2025

[Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications].

Hyo Young Lee, Eileen L Yoon

Abstract readEnglish AbstractReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Frontiers in endocrinology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hyo Young LeeDepartment of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea.
Eileen L YoonDepartment of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea.ORCID 0000-0003-0474-048X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A recent major change has occurred in the nomenclature of nonalcoholic fatty liver disease (NAFLD). From the multi-society Delphi consensus statement proposed a new term: metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023. The term "nonalcoholic" was regarded as misleading on multiple grounds. Firstly, it failed to reflect the disease's metabolic origins. Secondly, it hindered patients' understanding. Thirdly, the terms "nonalcoholic" and "fatty" were regarded as stigmatising by patients and physicians in the field. The proposal of MASLD was a response to these concerns. Since its introduction, the Korean Association for the Study of the Liver has also introduced the new Korean term for MASLD, previously the NAFLD. This article will briefly introduce the new MASLD diagnostic criteria and discuss their implications.

Indexed as

Fatty LiverNon-alcoholic Fatty Liver DiseaseHumansTerminology as TopicCardiometabolic risk factorsMetabolic dysfunctionNon-alcoholic fatty liver diseaseSteatotic liver

Identifiers

PMID40276829
PMCPMC12285424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.